Centene (CNC) reported $46.62 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 15.4%. EPS of $2.90 for the same period compares to $2.26 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $43.47 billion, representing a surprise of +7.24%. The company delivered an EPS surprise of +22.88%, with the consensus EPS estimate being $2.36.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Centene performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total Medical Health (Benefits) loss Ratios -Total Ratio (HBR): 87.1% versus 87.9% estimated by five analysts on average.
- Membership Medicaid - High Acuity Medicaid: 1.59 million versus the three-analyst average estimate of 1.59 million.
- Membership by line of business - Medicaid: 12.96 million compared to the 12.94 million average estimate based on three analysts.
- SG&A Expense Ratio: 7.9% versus 8.4% estimated by three analysts on average.
- Revenues- Premium and service revenues: $42.49 billion versus $40.12 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +16.9% change.
- Revenues- Premium: $41.71 billion compared to the $39.35 billion average estimate based on five analysts. The reported number represents a change of +17.4% year over year.
- Revenues- Service: $777 million versus $768.54 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -3.8% change.
- Revenues- Premium tax: $4.13 billion versus the five-analyst average estimate of $3.52 billion. The reported number represents a year-over-year change of +1.5%.
- Revenues- Premium and service revenues- Commercial: $10.15 billion compared to the $9.04 billion average estimate based on three analysts. The reported number represents a change of +30.9% year over year.
- Revenues- Premium and service revenues- Medicare: $8.76 billion versus $8.54 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +47.6% change.
- Revenues- Premium and service revenues- Medicaid: $22.30 billion compared to the $21.45 billion average estimate based on three analysts. The reported number represents a change of +3.9% year over year.
- Revenues- Premium and service revenues- Other: $1.28 billion versus $1.22 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
View all Key Company Metrics for Centene here>>>
Shares of Centene have returned +2.2% over the past month versus the Zacks S&P 500 composite's -4.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Centene Corporation (CNC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.